Feasibility of gastric cancer organoid models for personalized drug screening

doi:10.12307/2025.532

Abstract

Abstract: BACKGROUND: Postoperative adjuvant chemotherapy is a common method for the treatment of gastric cancer, but the curative effect of chemotherapy in different patients varies considerably. A new pre-clinical treatment model is needed to guide personalized drug therapy for patients with gastric cancer.
OBJECTIVE: To construct organoid model based on gastric cancer tissue and investigate its application in personalized drug screening.
METHODS: The tissue samples of 20 patients with gastric cancer were collected, digested and decomposed, mixed with matrix glue, and cultured with organoid medium containing epidermal growth factor and fibroblast growth factor 10. Hematoxylin-eosin staining and immunohistochemical method were used to verify the homogeneity of pathological morphology and immune molecular markers of gastric cancer organoids and original tumor tissues. The feasibility of the established gastric cancer organoid model for drug screening was evaluated through drug sensitivity screening of six drugs including carboplatin, irinotecan, fluorouracil, oxaliplatin, paclitaxel, and epirubicin.
RESULTS AND CONCLUSION: Fourteen organoids of gastric cancer cases were successfully cultured. There were individual differences in morphology and growth characteristics of organoids. All organoids could be stably passed through, froze and resuscitated. Gastric cancer organoids retained the same morphological features and immunomolecular expression as primary tumor tissues. Six organoids showed different drug sensitivities to six chemotherapy drugs, which initially confirmed the feasibility of gastric cancer organoids as a drug screening model in vitro.

Key words: organoids, 3D culture model, chemotherapy, personalized therapy, gastric cancer, drug sensitivity

CLC Number:

Fan Hongkai, Guan Yingying, Wang Lumin, Zeng Fanwei, Yin Yirui. Feasibility of gastric cancer organoid models for personalized drug screening[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(25): 5345-5350.

Figures/Tables 5

References

[1] THRIFT AP, WENKER TN, EL-SERAG HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338-349.
[2] GAO H, KORN JM, FERRETTI S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318-1325.
[3] BLEIJS M, VAN DE WETERING M, CLEVERS H, et al. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38(15): e101654.
[4] KREPLER C, SPROESSER K, BRAFFORD P, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep. 2017;21(7):1953-1967.
[5] QIAN X, SONG H, MING GL. Brain organoids: advances, applications and challenges. Development. 2019;146(8):dev166074.
[6] LESAVAGE BL, SUHAR RA, BROGUIERE N, et al. Next-generation cancer organoids. Nat Mater. 2022;21(2):143-159.
[7] MCQUERRY JA, CHANG JT, BOWTELL DDL, et al. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. J Mol Med (Berl). 2017;95(11):1167-1178.
[8] ZHAI Z, YU X, YANG B, et al. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol. 2017;64:107-115.
[9] CRUCITTA S, CUCCHIARA F, MATHIJSSEN R, et al. Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treat Rev. 2022;104:102340.
[10] TUTTY MA, HOLMES S, PRINA-MELLO A. Cancer Cell Culture: The Basics and Two-Dimensional Cultures. Methods Mol Biol. 2023;2645:3-40.
[11] HABANJAR O, DIAB-ASSAF M, CALDEFIE-CHEZET F, et al. 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. Int J Mol Sci. 2021;22(22):12200.
[12] TAKAHASHI T. Organoids for Drug Discovery and Personalized Medicine. Annu Rev Pharmacol Toxicol. 2019;59:447-462.
[13] UKAI S, HONMA R, SAKAMOTO N, et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. Oncogene. 2020; 39(50):7265-7278.
[14] 曾云丽,王穗东,李怡然,等.1231例结直肠癌类器官培养成功率的影响因素分析[J].中华胃肠外科杂志,2023,26(8):780-786.
[15] ZU M, HAO X, NING J, et al. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Biomed Pharmacother. 2023;163:114751.
[16] WATANABE S, YOGO A, OTSUBO T, et al. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. BMC Cancer. 2022;22(1):489.
[17] NUCIFORO S, FOFANA I, MATTER MS, et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep. 2018;24(5):1363-1376.
[18] YANG H, CHENG J, ZHUANG H, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell. 2024;42(4):535-551.e8.
[19] KIM M, MUN H, SUNG CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991.
[20] SEINO T, KAWASAKI S, SHIMOKAWA M, et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22(3):454-467.e6.
[21] SCHMÄCHE T, FOHGRUB J, KLIMOVA A, et al. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. Mol Cancer. 2024;23(1):10.
[22] 胡蕾,陈伟,张世维,等.胃癌恶性腹水来源类器官培养与药物敏感性筛查[J].消化肿瘤杂志(电子版),2022,14(1):32-41.
[23] LI J, XU H, ZHANG L, et al. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening. J Cancer Res Clin Oncol. 2019;145(11):2637-2647.
[24] 吴铭,初新宇,付阳,等.乳腺癌类器官疾病模型的构建及其对化疗药物的敏感性试验[J].实用医学杂志,2023,39(12):1480-1486.
[25] HUO C, ZHANG X, GU Y, et al. Organoids: Construction and Application in Gastric Cancer. Biomolecules. 2023;13(5):875.
[26] XU H, JIAO D, LIU A, et al. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15(1):58.
[27] VENINGA V, VOEST EE. Tumor organoids: Opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39(9):1190-1201.
[28] POORNIMA K, FRANCIS AP, HODA M, et al. Implications of Three-Dimensional Cell Culture in Cancer Therapeutic Research. Front Oncol. 2022;12:891673.